Price$12.68+3.87 (+43.85%)
2026-04-142026-07-17
News · 26 weeks60-58%
2026-01-182026-07-12
Mix4290d
- SEC Filings17(40%)
- Insider12(29%)
- Other11(26%)
- Analyst2(5%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Climb Bio Inc.SCHEDULE 13G - Climb Bio, Inc. (0001768446) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Climb Bio Inc.SCHEDULE 13D/A - Climb Bio, Inc. (0001768446) (Subject)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Celebi Breanna Maurine4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 3 filed by new insider Celebi Breanna Maurine3 - Climb Bio, Inc. (0001768446) (Issuer)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- INSIDERPresident and CEO Brennan Aoife converted options into 68,750 shares and sold $406,979 worth of shares (30,902 units at $13.17) as part of a pre-agreed trading plan, increasing direct ownership by 76% to 87,731 units (SEC Form 4) (withholding tax)4 - Climb Bio, Inc. (0001768446) (Issuer)
- SECSEC Form 144 filed by Climb Bio Inc.144 - Climb Bio, Inc. (0001768446) (Subject)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 424B5 filed by Climb Bio Inc.424B5 - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an enc
- SECSEC Form EFFECT filed by Climb Bio Inc.EFFECT - Climb Bio, Inc. (0001768446) (Filer)
- SECSEC Form 424B3 filed by Climb Bio Inc.424B3 - Climb Bio, Inc. (0001768446) (Filer)
- INSIDERSEC Form 4 filed by Director Ra Capital Management, L.P.4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Levin Andrew David4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Drapkin Kimberlee C4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Williams Douglas E4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Cumbo Alexander4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomas Stephen Basil4 - Climb Bio, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 4 filed by Director Dunn Judith4 - Climb Bio, Inc. (0001768446) (Issuer)
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- ANALYSTGuggenheim initiated coverage on Climb Bio with a new price targetGuggenheim initiated coverage of Climb Bio with a rating of Buy and set a new price target of $35.00
- SECSEC Form 8-K filed by Climb Bio Inc.8-K - Climb Bio, Inc. (0001768446) (Filer)
- PRClimb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued DevelopmentCompany to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026 WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody. Clinical data demonstrated a favorable initial safety profile, supporting continued development of CLYM116 in IgA nephropathy (IgAN). These data will be pres
CLYM FAQ
6 questionsWhere does CLYM stock trade?
Climb Bio Inc. (CLYM) is listed on NASDAQ.What sector and industry is CLYM in?
Climb Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Climb Bio Inc. go public?
Climb Bio Inc. (CLYM) completed its IPO in 2021.What are analysts saying about CLYM?
Climb Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $3500.00 price target on 2026-06-08. Recent price targets range from $1200.00 to $3500.00.What companies are similar to CLYM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CLYM side-by-side with any of them on Quantisnow.How can I track CLYM on Quantisnow?
Quantisnow aggregates Climb Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLYM to receive live email and push alerts on every new disclosure.